Inovio Pharma (INO) Misses Q4 EPS by $1.13

Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($1.45), $1.13 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $1.77 million versus the consensus estimate of $2.84 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• H.C. Wainwright Reiterates Neutral Rating on Inovio Pharmaceuticals (INO)